• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

疫苗诱导的免疫性血小板减少症和血栓形成(VITT)——来自临床病例、体外研究和小鼠模型的见解

Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT)-Insights from Clinical Cases, In Vitro Studies and Murine Models.

作者信息

Dabbiru Venkata A S, Müller Luisa, Schönborn Linda, Greinacher Andreas

机构信息

Institut für Transfusionsmedizin, Universitätsmedizin Greifswald, 17489 Greifswald, Germany.

出版信息

J Clin Med. 2023 Sep 22;12(19):6126. doi: 10.3390/jcm12196126.

DOI:10.3390/jcm12196126
PMID:37834770
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10573542/
Abstract

An effective worldwide vaccination campaign started and is still being carried out in the face of the coronavirus disease 2019 (COVID-19) pandemic. While vaccines are great tools to confront the pandemic, predominantly adenoviral vector-based vaccines can cause a rare severe adverse effect, termed vaccine-induced immune thrombocytopenia and thrombosis (VITT), in about 1 in 100,000 vaccinated individuals. VITT is diagnosed 5-30 days post-vaccination and clinically characterized by thrombocytopenia, strongly elevated D-dimer levels, platelet-activating anti-platelet factor 4 (PF4) antibodies and thrombosis, especially at atypical sites such as the cerebral venous sinus and/or splanchnic veins. There are striking similarities between heparin-induced thrombocytopenia (HIT) and VITT. Both are caused by anti-PF4 antibodies, causing platelet and leukocyte activation which results in massive thrombo-inflammation. However, it is still to be determined why PF4 becomes immunogenic in VITT and which constituent of the vaccine triggers the immune response. As VITT-like syndromes are increasingly reported in patients shortly after viral infections, direct virus-PF4 interactions might be most relevant. Here we summarize the current information and hypotheses on the pathogenesis of VITT and address in vivo models, especially murine models for further studies on VITT.

摘要

面对2019冠状病毒病(COVID-19)大流行,一场有效的全球疫苗接种运动已经启动,并且仍在进行中。虽然疫苗是应对大流行的有力工具,但主要基于腺病毒载体的疫苗可能会在每10万名接种者中导致约1人出现一种罕见的严重不良反应,称为疫苗诱导的免疫性血小板减少症和血栓形成(VITT)。VITT在接种疫苗后5至30天被诊断出来,其临床特征为血小板减少、D-二聚体水平大幅升高、血小板活化抗血小板因子4(PF4)抗体以及血栓形成,尤其是在非典型部位,如脑静脉窦和/或内脏静脉。肝素诱导的血小板减少症(HIT)和VITT之间存在显著相似之处。两者均由抗PF4抗体引起,导致血小板和白细胞活化,进而引发大规模血栓炎症。然而,PF4在VITT中为何具有免疫原性以及疫苗的哪种成分触发免疫反应仍有待确定。由于在病毒感染后不久的患者中越来越多地报告了类似VITT的综合征,病毒与PF4的直接相互作用可能最为关键。在此,我们总结了目前关于VITT发病机制的信息和假说,并介绍了体内模型,特别是用于VITT进一步研究的小鼠模型。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2206/10573542/f6d0035f1b61/jcm-12-06126-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2206/10573542/938335b41b1f/jcm-12-06126-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2206/10573542/f80712dc9236/jcm-12-06126-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2206/10573542/72bf64c8e435/jcm-12-06126-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2206/10573542/1013e58e5d75/jcm-12-06126-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2206/10573542/4bdf350b7ff9/jcm-12-06126-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2206/10573542/f6d0035f1b61/jcm-12-06126-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2206/10573542/938335b41b1f/jcm-12-06126-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2206/10573542/f80712dc9236/jcm-12-06126-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2206/10573542/72bf64c8e435/jcm-12-06126-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2206/10573542/1013e58e5d75/jcm-12-06126-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2206/10573542/4bdf350b7ff9/jcm-12-06126-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2206/10573542/f6d0035f1b61/jcm-12-06126-g006.jpg

相似文献

1
Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT)-Insights from Clinical Cases, In Vitro Studies and Murine Models.疫苗诱导的免疫性血小板减少症和血栓形成(VITT)——来自临床病例、体外研究和小鼠模型的见解
J Clin Med. 2023 Sep 22;12(19):6126. doi: 10.3390/jcm12196126.
2
Coronavirus (COVID-19) Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) (Archived)冠状病毒(COVID-19)疫苗诱导的免疫性血栓性血小板减少症(VITT)(存档)
3
Retrospective review COVID-19 vaccine induced thrombotic thrombocytopenia and cerebral venous thrombosis-what can we learn from the immune response.回顾性分析 COVID-19 疫苗诱导的血栓性血小板减少症和脑静脉血栓形成——我们可以从免疫反应中学到什么。
Clin Imaging. 2022 Oct;90:63-70. doi: 10.1016/j.clinimag.2022.06.020. Epub 2022 Jul 15.
4
Potential mechanisms of vaccine-induced thrombosis.疫苗诱导血栓形成的潜在机制。
Eur J Intern Med. 2022 Nov;105:1-7. doi: 10.1016/j.ejim.2022.08.002. Epub 2022 Aug 8.
5
Persistence of Ad26.COV2.S-associated vaccine-induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies.Ad26.COV2.S 相关疫苗诱导的免疫性血栓性血小板减少症(VITT)的持续存在和 VITT 抗体的特异性检测。
Am J Hematol. 2022 May;97(5):519-526. doi: 10.1002/ajh.26488. Epub 2022 Feb 21.
6
Thrombotic anti-PF4 immune disorders: HIT, VITT, and beyond.血栓性抗 PF4 免疫性疾病:HIT、VITT 及其他。
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):1-10. doi: 10.1182/hematology.2023000503.
7
Anti-PF4 immunothrombosis without proximate heparin or adenovirus vector vaccine exposure.无近期肝素或腺病毒载体疫苗接触的抗 PF4 免疫血栓形成。
Blood. 2023 Dec 28;142(26):2305-2314. doi: 10.1182/blood.2023022136.
8
Antibodies against platelet factor 4 and the risk of cerebral venous sinus thrombosis in patients with vaccine-induced immune thrombotic thrombocytopenia.抗血小板因子 4 抗体与疫苗诱导的免疫性血栓性血小板减少症患者发生脑静脉窦血栓的风险。
J Thromb Haemost. 2023 Oct;21(10):2833-2843. doi: 10.1016/j.jtha.2023.06.026. Epub 2023 Jun 30.
9
Mechanisms of Immunothrombosis in Vaccine-Induced Thrombotic Thrombocytopenia (VITT) Compared to Natural SARS-CoV-2 Infection.疫苗诱导的免疫性血栓性血小板减少症(VITT)与自然 SARS-CoV-2 感染中免疫血栓形成的机制比较。
J Autoimmun. 2021 Jul;121:102662. doi: 10.1016/j.jaut.2021.102662. Epub 2021 May 19.
10
Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT).疫苗诱导的免疫性血栓性血小板减少症(VITT)的发病机制。
Semin Hematol. 2022 Apr;59(2):97-107. doi: 10.1053/j.seminhematol.2022.02.004. Epub 2022 Feb 23.

引用本文的文献

1
COVID-19 vaccination, all-cause mortality, and hospitalization for cancer: 30-month cohort study in an Italian province.2019冠状病毒病疫苗接种、全因死亡率和癌症住院情况:意大利某省的30个月队列研究
EXCLI J. 2025 Jul 1;24:690-707. doi: 10.17179/excli2025-8400. eCollection 2025.
2
Spontaneous Reports of Adverse Reactions with Fatal Outcomes After COVID-19 Vaccination During the National Vaccination Campaign in Sweden.瑞典全国疫苗接种运动期间新冠病毒疫苗接种后出现致命后果的不良反应自发报告
Clin Drug Investig. 2025 Aug 12. doi: 10.1007/s40261-025-01466-3.
3
Thromboembolic Events in the Era of COVID-19: A Detailed Narrative Review.

本文引用的文献

1
Adenovirus-Associated Thrombocytopenia, Thrombosis, and VITT-like Antibodies.腺病毒相关的血小板减少、血栓形成及VITT样抗体
N Engl J Med. 2023 Aug 10;389(6):574-577. doi: 10.1056/NEJMc2307721.
2
Heparin-Induced Thrombotic Thrombocytopenia (HITT) and Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT): Similar but Different.肝素诱导的血栓性血小板减少症 (HITT) 和疫苗诱导的免疫性血栓性血小板减少症 (VITT):相似但不同。
Methods Mol Biol. 2023;2663:405-415. doi: 10.1007/978-1-0716-3175-1_26.
3
Investigation of anti-PF4 versus anti-PF4/heparin reactivity using fluid-phase enzyme immunoassay for 4 anti-PF4 disorders: classic heparin-induced thrombocytopenia (HIT), autoimmune HIT, vaccine-induced immune thrombotic thrombocytopenia, and spontaneous HIT.
COVID-19 时代的血栓栓塞事件:详细叙述性综述
Can J Infect Dis Med Microbiol. 2025 Mar 4;2025:3804576. doi: 10.1155/cjid/3804576. eCollection 2025.
4
Applying the lessons learned from the COVID-19 pandemic to the next generation of nanocarrier-based vaccines.将从新冠疫情中吸取的经验教训应用于下一代基于纳米载体的疫苗。
Nanomedicine (Lond). 2025 Jan;20(2):117-119. doi: 10.1080/17435889.2024.2418280. Epub 2024 Nov 6.
采用液相酶免疫分析法对 4 种抗 PF4 疾病(经典肝素诱导的血小板减少症(HIT)、自身免疫性 HIT、疫苗诱导的免疫性血栓性血小板减少症和自发性 HIT)进行抗 PF4 与抗 PF4/肝素反应性的研究。
J Thromb Haemost. 2023 Aug;21(8):2268-2276. doi: 10.1016/j.jtha.2023.04.034. Epub 2023 May 12.
4
Platelet factor 4 triggers thrombo-inflammation by bridging innate and adaptive immunity.血小板因子 4 通过桥接先天免疫和适应性免疫触发血栓炎症。
Int J Lab Hematol. 2023 Jun;45 Suppl 2:11-22. doi: 10.1111/ijlh.14075. Epub 2023 May 7.
5
Vaccine-induced immune thrombotic thrombocytopenia.疫苗诱导的免疫性血栓性血小板减少症。
Blood. 2023 Apr 6;141(14):1659-1665. doi: 10.1182/blood.2022017696.
6
Monoclonal gammopathy of thrombotic/thrombocytopenic significance.具有血栓形成/血小板减少意义的单克隆丙种球蛋白病
Blood. 2023 Apr 6;141(14):1772-1776. doi: 10.1182/blood.2022018797.
7
Laboratory Testing for Heparin-Induced Thrombocytopenia and Vaccine-Induced Immune Thrombotic Thrombocytopenia Antibodies: A Narrative Review.肝素诱导的血小板减少症和疫苗诱导的免疫性血栓性血小板减少症抗体的实验室检测:一篇叙述性综述。
Semin Thromb Hemost. 2023 Sep;49(6):621-633. doi: 10.1055/s-0042-1758818. Epub 2022 Dec 1.
8
NETosis and thrombosis in vaccine-induced immune thrombotic thrombocytopenia.疫苗诱导免疫性血栓性血小板减少症中的 NETosis 和血栓形成。
Nat Commun. 2022 Sep 5;13(1):5206. doi: 10.1038/s41467-022-32946-1.
9
Quantitative interpretation of PF4/heparin-EIA optical densities in predicting platelet-activating VITT antibodies.定量解读 PF4 肝素-EIA 光密度在预测血小板激活型 VITT 抗体中的作用。
J Thromb Haemost. 2022 Nov;20(11):2579-2586. doi: 10.1111/jth.15862. Epub 2022 Sep 4.
10
Temporal presentations of heparin-induced thrombocytopenia following cardiac surgery: A single-center, retrospective cohort study.肝素诱导的血小板减少症在心脏手术后的时间表现:一项单中心、回顾性队列研究。
J Thromb Haemost. 2022 Nov;20(11):2601-2616. doi: 10.1111/jth.15826. Epub 2022 Aug 11.